Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Profile Name | ATM K2811fs |
| Gene Variant Detail | |
| Relevant Treatment Approaches | PARP Inhibitor (Pan) |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA and Talzenna (talazoparib) combination treatment resulted in increased cell death and inhibition of proliferation in breast cancer cell lines compared to Talzenna (talazoparib) alone in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | CHIR99021 + Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with CHIR99021 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Talzenna (talazoparib) in culture, resulting in a synergistic effect (PMID: 33589588). | 33589588 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | CYT01B + Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, CYT01B and Talzenna (talazoparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). | detail... |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | LY2090314 + Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with LY2090314 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Talzenna (talazoparib) in culture, resulting in a synergistic effect (PMID: 33589588). | 33589588 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | SN-38 + Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Ewing sarcoma cells treated with SN-38 combined with Talazoparib (BMN-673) resulted in synergism, demonstrating reduced cell viability in culture (PMID: 26438158). | 26438158 |
| Unknown unknown | lung small cell carcinoma | not applicable | PARP Inhibitor (Pan) | Talazoparib | Phase I | Actionable | In a Phase I trial, Talazoparib (BMN-673) treatment in patients with lung small cell carcinoma resulted in an objective response rate of 9% (2/23), including two patients with a partial response, and four patients with stable disease for at least 16 weeks (PMID: 28242752). | 28242752 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | Talazoparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the Talazoparib (BMN-673) selective PARP1/2 inhibitor demonstrated antitumor activity on a variety of cell lines and xenografts with defects in DNA repair (PMID: 23881923). | 23881923 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | Talazoparib | Phase I | Actionable | In a Phase I trial, Talazoparib (BMN-673) treatment in patients with Ewing sarcoma did not result in any objective responses, however, resulted in a clinical benefit rate of 23% (PMID: 28242752). | 28242752 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | Talazoparib + Temozolomide | Preclinical - Cell culture | Actionable | In a preclinical study, Ewing sarcoma cells treated with Temodar (temozolomide) combined with Talazoparib (BMN-673) resulted in strong synergism, demonstrating decreased cell viability in culture (PMID: 26438158). | 26438158 |
| Unknown unknown | prostate cancer | not applicable | PARP Inhibitor (Pan) | Abiraterone + Prednisone + Veliparib | Phase II | Actionable | In a Phase II (NCI 9012) trial, addition of Veliparib (ABT-888) to Zytiga (abiraterone) and Prednisone did not improve PSA response rate (72.4% vs 63.9%, p=0.27), measurable disease response rate (52.2% vs 45.0%, p=0.51), or median progression-free survival (10.1 vs 11.0 months, p=0.99) in patients with metastatic castration-resistant prostate cancer (PMID: 29261439; NCT01576172). | 29261439 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA and Veliparib (ABT-888) combination treatment resulted in increased cell death and inhibition of proliferation in breast cancer cell lines compared to Veliparib (ABT-888) alone in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | multiple myeloma | not applicable | PARP Inhibitor (Pan) | B02 + Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of B02 resulted in increased sensitivity to Veliparib (ABT-888), in a multiple myeloma cell line in culture, leading decreased cell viability (PMID: 26719576). | 26719576 |
| Unknown unknown | non-Hodgkin lymphoma | not applicable | PARP Inhibitor (Pan) | Bendamustine + Rituximab + Veliparib | Phase I | Actionable | In a Phase I trial, seven patients with non-Hodgkin lymphoma treated with a combination of Veliparib (ABT-888), Bendamustine, and Rituxan (rituximab) demonstrated an overall response rate of 86% (6/7) and a complete response rate of 71% (5/7), and a progression free survival of 14.2 months (PMID: 28314788; NCT01326702). | 28314788 |
| Unknown unknown | follicular lymphoma | not applicable | PARP Inhibitor (Pan) | Bendamustine + Rituximab + Veliparib | Phase I | Actionable | In a Phase I trial, five patients with follicular lymphoma treated with a combination of Bendamustine, Rituxan (rituximab), and Veliparib (ABT-888) demonstrated a complete response (PMID: 28314788; NCT01326702). | 28314788 |
| Unknown unknown | follicular lymphoma | not applicable | PARP Inhibitor (Pan) | Bendamustine + Veliparib | Phase I | Actionable | In a Phase I trial, a patient with follicular lymphoma treated with a combination of Veliparib (ABT-888) and Bendamustine demonstrated a complete response (PMID: 28314788; NCT01326702). | 28314788 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | Bendamustine + Veliparib | Phase I | Actionable | In a Phase I trial, the combination of Bendamustine and Veliparib (ABT-888) resulted in stable disease in 63% (12/19) of patients with advanced solid tumors (PMID: 28314788; NCT01326702). | 28314788 |
| Unknown unknown | lymphoma | not applicable | PARP Inhibitor (Pan) | Bendamustine + Veliparib | Phase I | Actionable | In a Phase I trial, seven patients with lymphoma treated with a combination of Veliparib (ABT-888) and Bendamustine demonstrated an overall response rate of 71% (5/7) and complete response rate of 57% (4/7) and progression free survival of 6.9 months (PMID: 28314788; NCT01326702). | 28314788 |
| Unknown unknown | multiple myeloma | not applicable | PARP Inhibitor (Pan) | Bendamustine + Veliparib | Phase I | Actionable | In a Phase I trial, a patient with multiple myeloma demonstrated a partial response when treated with a combination of Bendamustine and Veliparib (ABT-888) (PMID: 28314788; NCT01326702). | 28314788 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | PARP Inhibitor (Pan) | Carboplatin + Paclitaxel + Veliparib | Phase II | Actionable | In a Phase II trial, the combination of Veliparib (ABT-888) with Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in both an improved median PFS (5.8 mo vs 4.2 mo) and median OS (11.7 mo vs 9.1 mo) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in patients with non-small cell lung carcinoma (PMID: 27803064). | 27803064 |
| Unknown unknown | acute myeloid leukemia | not applicable | PARP Inhibitor (Pan) | Carboplatin + Topotecan + Veliparib | Phase I | Actionable | In a Phase I trial, the combination of Hycamtin (topotecan), Paraplatin (carboplatin), and Veliparib (ABT-888) resulted in a response rate of 25% (19/77) in patients with acute myeloid leukemia (PMID: 27551000). | 27551000 |
| Unknown unknown | leukemia | not applicable | PARP Inhibitor (Pan) | Carboplatin + Topotecan + Veliparib | Phase I | Actionable | In a Phase I trial, the combination of Hycamtin (topotecan), Paraplatin (carboplatin), and Veliparib (ABT-888) resulted in an overall response rate of 33% (33/99) in leukemia patients and a response rate of 64% (14/22) in patients with aggressive myeloproliferative neoplasms or chronic myelomonocytic leukemia (PMID: 27551000). | 27551000 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | Carboplatin + Veliparib | Phase I | Actionable | In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in patients with metastatic breast cancer, with 18.6 % (9/43) achieving partial response and 48.8% (21/43) achieving stable disease (J Clin Oncol. 2014;32(suppl):abstr 1074). | detail... |
| Unknown unknown | Her2-receptor negative breast cancer | not applicable | PARP Inhibitor (Pan) | Cisplatin + Veliparib + Vinorelbine | Phase I | Actionable | In a Phase I trial, Veliparib (ABT-888) in combination with Platinol (cisplatin) and Navelbine (vinorelbine) resulted in a complete response in 4% (2/48), partial response in 31% (15/48), and stable disease in 44% (31/48) of patients with Erbb2 (Her2) negative breast cancer (PMID: 26801247). | 26801247 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | CYT01B + Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, CYT01B and Veliparib (ABT-888) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). | detail... |
| Unknown unknown | multiple myeloma | not applicable | PARP Inhibitor (Pan) | Dinaciclib + Veliparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Veliparib (ABT-888) and Dinaciclib (SCH 727965) had a synergistic effect on decreasing survival of multiple myeloma cell lines in culture, and resulted in delayed tumor growth and improved survival of multiple myeloma cell line xenograft models compared to either agent alone (PMID: 26719576). | 26719576 |
| Unknown unknown | pancreatic ductal adenocarcinoma | not applicable | PARP Inhibitor (Pan) | Fluorouracil + Oxaliplatin + Veliparib | Phase Ib/II | Actionable | In a Phase I/II trial, Veliparib (ABT-888) in combination with Adrucil (fluorouracil) and Eloxatin (oxaliplatin) demonstrated safety, and resulted in an objective response rate of 26% (15/58, 4 complete responses, 11 partial responses), a disease control rate of 52%, a progression-free survival of 4.0 months, and an overall survival of 7.8 months in patients with metastatic pancreatic ductal adenocarcinoma (PMID: 32669374; NCT01489865). | 32669374 |
| Unknown unknown | colon cancer | not applicable | PARP Inhibitor (Pan) | Irinotecan + Veliparib | Phase I | Actionable | In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 50% (2/4) of patients with colon cancer (PMID: 26842236). | 26842236 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | Irinotecan + Veliparib | Phase I | Actionable | In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 33% (3/9) of patients with advanced breast cancer (PMID: 26842236). | 26842236 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | Irinotecan + Veliparib | Phase I | Actionable | In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 19% (6/31) and stable disease in 42% (13/31) of patients with advanced solid tumors (PMID: 26842236). | 26842236 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | SN-38 + Veliparib | Preclinical | Actionable | In a preclinical study, Ewing sarcoma cells treated with SN-38 combined with Veliparib (ABT-888) resulted in synergism, demonstrating reduced cell viability in culture (PMID: 26438158). | 26438158 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | Temozolomide + Veliparib | Preclinical | Actionable | In a preclinical study, Ewing sarcoma cells treated with Temodar (temozolomide) combined with Veliparib (ABT-888) resulted in strong synergism, demonstrating reduced cell viability in culture (PMID: 26438158). | 26438158 |
| Unknown unknown | ovarian carcinoma | not applicable | PARP Inhibitor (Pan) | Topotecan + Veliparib | Phase I | Actionable | In a Phase I trial, the combination of Veliparib (ABT-888) and topotecan demonstrated safety and tolerability, and resulted in an objective response rate of 9% (4/45; 1 complete response and 3 partial responses) and stable disease in 21 patients with ovarian carcinoma (PMID: 29138343; NCT01012817). | 29138343 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | Topotecan + Veliparib | Phase I | Actionable | In a Phase I trial, the combination of Veliparib (ABT-888) and topotecan demonstrated safety and tolerability, and resulted in an objective response rate of 10% (5/51; 1 complete response and 4 partial responses) and stable disease for at least 4 months in 43% (22/51) of patients with advanced solid tumors, with the majority of the patients having ovarian, fallopian tube, or primary peritoneal cancer (PMID: 29138343; NCT01012817). | 29138343 |
| Unknown unknown | malignant astrocytoma | no benefit | PARP Inhibitor (Pan) | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, Veliparib (ABT-888) had a very limited effect on the cell viability of multiple cultured pediatric high grade astrocytoma cell lines (PMID: 26351319). | 26351319 |
| Unknown unknown | brain stem glioma | no benefit | PARP Inhibitor (Pan) | Veliparib | Preclinical - Cell culture | Actionable | In a preclinical study, Veliparib (ABT-888) had a very limited effect on the cell viability of multiple cultured pediatric diffuse intrinsic pontine glioma cell lines (PMID: 26351319). | 26351319 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | BGP-15 | Preclinical - Cell culture | Actionable | In a preclinical study, BGP-15 induced apoptosis and inhibited growth of breast cancer cells in culture (PMID: 22661288). | 22661288 |
| Unknown unknown | colon cancer | not applicable | PARP Inhibitor (Pan) | BGP-15 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, BGP-15 induced apoptosis and inhibited growth of colon cancer cells in culture and in cell line xenograft models (PMID: 22661288). | 22661288 |
| Unknown unknown | prostate cancer | not applicable | PARP Inhibitor (Pan) | BGP-15 | Preclinical - Cell culture | Actionable | In a preclinical study, BGP-15 induced apoptosis and inhibited growth of prostate cancer cells in culture (PMID: 22661288). | 22661288 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA and Rubraca (rucaparib) combination treatment resulted in increased cell death and inhibition of proliferation in breast cancer cell lines compared to Rubraca (rucaparib) alone in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Birabresib + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Birabresib (OTX015) and Rubraca (rucaparib) resulted in a synergistic effect, demonstrating greater growth inhibition of ovarian cancer cells in culture compared to Birabresib (OTX015) treatment alone (PMID: 32927276). | 32927276 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | CCT241533 + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, CCT241533 enhanced the growth inhibition effect of Rubraca (rucaparib) in colorectal cancer cells in culture (PMID: 21239475). | 21239475 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | CHIR99021 + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with CHIR99021 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Rubraca (rucaparib) in culture, resulting in a synergistic effect (PMID: 33589588). | 33589588 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | CPI-0610 + Dasatinib + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination treatment of Sprycel (dasatinb), CPI-0610, and Rubraca (rucaparib) resulted in a synergistic effect, demonstrating greater inhibition of colony formation and higher levels of PARP cleavage in ovarian cancer cells in culture compared to double therapy combination treatments (PMID: 32927276). | 32927276 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | CPI-0610 + Rucaparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination treatment of Rubraca (rucaparib) and CPI-0610 resulted in a synergistic effect, demonstrating greater inhibition of cell growth and colony formation in cultured ovarian cancer cells and a 58% decrease in tumor weight in cell line xenograft models (PMID: 32927276). | 32927276 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | CPI-203 + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of CPI-203 and Rubraca (rucaparib) resulted in a synergistic effect, demonstrating greater growth inhibition of ovarian cancer cells in culture compared to CPI-203 treatment alone (PMID: 32927276). | 32927276 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | CYT01B + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, CYT01B and Rubraca (rucaparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). | detail... |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Dasatinib + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination treatment of Sprycel (dasatinb) and Rubraca (rucaparib) resulted in a synergistic effect, demonstrating inhibition of colony formation in ovarian cancer cells in culture (PMID: 32927276). | 32927276 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | JQ1 + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of JQ1 and Rubraca (rucaparib) resulted in a synergistic effect, demonstrating greater growth inhibition of ovarian cancer cells in culture compared to JQ1 treatment alone (PMID: 32927276). | 32927276 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | LY2090314 + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with LY2090314 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Rubraca (rucaparib) in culture, resulting in a synergistic effect (PMID: 33589588). | 33589588 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Molibresib + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Molibresib (GSK525762) and Rubraca (rucaparib) resulted in a synergistic effect, demonstrating greater growth inhibition of ovarian cancer cells in culture compared to Molibresib (GSK525762) treatment alone (PMID: 32927276). | 32927276 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Navitoclax + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Rubraca (rucaparib) and Navitoclax (ABT-263) resulted in a synergistic effect in ovarian cancer cell lines and patient-derived ovarian cancer cells in culture, and led to increased PARP cleavage compared to treatment with Navitoclax (ABT-263) alone (PMID: 32927276). | 32927276 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | NU6027 + Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, NU6027 enhanced the efficacy of Rubraca (rucaparib) in breast cancer cells in culture, resulting in a greater decreased cell survival (PMID: 21730979). | 21730979 |
| Unknown unknown | ovarian carcinoma | not applicable | PARP Inhibitor (Pan) | Rucaparib | Phase II | Actionable | In a Phase II trial, Rubraca (rucaparib) demonstrated activity in patients with platinum-sensitive high-grade ovarian carcinoma, with patients in the BRCA mutant and BRCA wild-type with high genomic loss-of-heterozygosity subgroups demonstrating increased progression-free survival compared to the BRCA wild-type with low genomic loss-of-heterozygosity subgroup (PMID: 27908594). | 27908594 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | Rucaparib | Phase I | Actionable | In a Phase I trial, Rubraca (rucaparib) was well-tolerated and demonstrated preliminary efficacy, with a disease control rate of 86% (6/7), in patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 2585)). | detail... |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Rucaparib | FDA approved | Actionable | In a Phase III trial that supported FDA approval, Rubraca (rucaparib) maintenance therapy significantly improved median progression-free survival compared to placebo (10.8 vs 5.4 mo, HR=0.36, p<0.0001) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who responded to platinum-based therapy (PMID: 28916367; NCT01968213). | 28916367 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | Rucaparib + Temozolomide | Preclinical - Cell line xenograft | Actionable | In a preclinical trial, Rubraca (rucaparib) sensitized colorectal cancer cell lines to Temodar (temozolomide) treatment both in culture and in cell line xenograft models (PMID: 17363489). | 17363489 |
| Unknown unknown | ovarian cancer | no benefit | PARP Inhibitor (Pan) | Rucaparib + Venetoclax | Preclinical - Cell culture | Actionable | In a preclinical study, ovarian cancer cells did not respond to the combination treatment of Rubraca (rucaparib) and Venclexta (venetoclax) in culture (PMID: 32927276). | 32927276 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | CHIR99021 + Simmiparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination therapy of CHIR99021 and Simmiparib resulted in a synergistic effect in colorectal cancer cells with either BRCA1/2 proficiency or BRCA2 deficiency in culture, demonstrating increased cell cycle arrest, apoptotic cell death, and decreased cell survival (PMID: 33589588). | 33589588 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | LY2090314 + Simmiparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination therapy of LY2090314 and Simmiparib resulted in a synergistic effect in colorectal cancer cells with either BRCA1/2 proficiency or BRCA2 deficiency in culture, demonstrating increased cell cycle arrest, apoptotic cell death, and decreased cell survival, and led to inhibition of tumor growth, increased double-strand DNA breaks, and elevated cleaved caspase 3 in cell line xenograft models (PMID: 33589588). | 33589588 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | Fluzoparib | Phase I | Actionable | In a Phase I trial, Fluzoparib treatment was well tolerated, and among evaluable breast cancer patients resulted in an overall response rate (ORR) of 7.7% (1/13) and stable disease at 24 weeks in 5/13, for a disease control rate of 23.1%, and a median progression-free survival (mPFS) of 3.5 months in patients dosed at >120mg/d, with 1 patient still on treatment at 28 months (PMID: 32694901; NCT03509636). | 32694901 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Fluzoparib | Phase I | Actionable | In a Phase I trial, Fluzoparib treatment was well tolerated, and among evaluable ovarian cancer patients resulted in an overall response rate (ORR) of 8.1% (3/37) and stable disease at 24 weeks in 14/37, for a disease control rate of 45.9%, and a median progression-free survival (mPFS) of 7.2 months in patients dosed at >120mg/d, with an ORR of 30% (3/10) and mPFS of 9.3 months in platinum-sensitive patients (PMID: 32694901; NCT03509636). | 32694901 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Fluzoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Fluzoparib inhibited DNA-damage-induced PARylation in high-grade serous ovarian cancer cell lines in culture, however, the cells demonstrated resistance to Fluzoparib treatment (PMID: 30949414). | 30949414 |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | PARP Inhibitor (Pan) | Fluzoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Fluzoparib inhibited DNA-damage-induced PARylation in breast cancer cell lines in culture, however, the cells demonstrated resistance to Fluzoparib treatment (PMID: 30949414). | 30949414 |
| Unknown unknown | female reproductive organ cancer | not applicable | PARP Inhibitor (Pan) | Pamiparib | Phase I | Actionable | In a Phase I trial, Pamiparib (BGB-290) treatment resulted in objective response in 43% (10/23) of patients with gynecological cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723). | detail... |
| Unknown unknown | pancreatic cancer | not applicable | PARP Inhibitor (Pan) | Pamiparib + Tislelizumab | Case Reports/Case Series | Actionable | In a Phase Ib trial, the combination therapy of of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in patients with pancreatic cancer resulted in one partial response and stable disease for greater than 6 months in two patients (J Clin Oncol 35, 2017 (suppl; abstr 3013)). | detail... |
| Unknown unknown | uterine cancer | not applicable | PARP Inhibitor (Pan) | Pamiparib + Tislelizumab | Case Reports/Case Series | Actionable | In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) resulted in a partial response in a patient with uterine cancer (J Clin Oncol 35, 2017 (suppl; abstr 3013)). | detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | Pamiparib + Tislelizumab | Phase Ib/II | Actionable | In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in patients with advanced solid tumors was well-tolerated and resulted in an objective response in 20% (10/49), with two complete responses and eight partial responses, stable disease in 32% (16/49), a disease control rate of 53% (26/49), and a clinical benefit of 39% (PMID: 31378459; NCT02660034). | 31378459 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Pamiparib + Tislelizumab | Case Reports/Case Series | Actionable | In a Phase Ib trial, the combination therapy of Tislelizumab (BGB-A317) and Pamiparib (BGB-290) in ovarian cancer patients resulted in a clinical response in 26% (9/34) with two complete responses and seven partial responses (PMID: 31378459; NCT02660034). | 31378459 |
| Unknown unknown | lung non-small cell carcinoma | not applicable | PARP Inhibitor (Pan) | Cisplatin + PJ34 | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Platinol (cisplatin) and PJ34 worked synergistically to induce cell death in non-small cell lung carcinoma cells in culture (PMID: 23428903). | 23428903 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | PJ34 | Preclinical - Cell culture | Actionable | In a preclinical study, PJ34 induced cell cycle arrest in a variety of tumor cell lines in culture (PMID: 21840268). | 21840268 |
| Unknown unknown | glioblastoma | not applicable | PARP Inhibitor (Pan) | A-966492 + Radiotherapy + Topotecan | Preclinical - Cell culture | Actionable | In a preclinical study, the combination treatment of A-966492 and Hycamtin (topotecan) resulted in enhanced radiosensitivity in glioblastoma cells in culture, demonstrating a greater reduction in cell survival (PMID: 28797568). | 28797568 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA and Zejula (niraparib) combination treatment resulted in increased cell death and inhibition of proliferation in breast cancer cell lines compared to Zejula (niraparib) alone in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | ovary epithelial cancer | not applicable | PARP Inhibitor (Pan) | Bevacizumab + Niraparib | Phase I | Actionable | In a Phase I trial, Avastin (bevacizumab) and Zejula (niraparib) combination treatment resulted in complete response in 8% (1/12), partial response in 33% (4/12), and a disease control rate of 91% in platinum-sensitive ovarian cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 5555)). | detail... |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | CHIR99021 + Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with CHIR99021 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Zejula (niraparib) in culture, resulting in a synergistic effect (PMID: 33589588). | 33589588 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | CYT01B + Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, CYT01B and Zejula (niraparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). | detail... |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | LY2090314 + Niraparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with LY2090314 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Zejula (niraparib) in culture, resulting in a synergistic effect (PMID: 33589588). | 33589588 |
| Unknown unknown | malignant astrocytoma | not applicable | PARP Inhibitor (Pan) | Niraparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, pediatric high grade astrocytoma cell lines treated with Zejula (niraparib) demonstrated decreased cell viability and proliferation in culture, and a small survival benefit in xenograft models (PMID: 26351319). | 26351319 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Niraparib | Phase I | Actionable | In a Phase I clinical trial, Zejula (niraparib) demonstrated safety and preliminary efficacy, resulted in a durable partial response (PR) in 67% (2/3) of patients with plantinum-sensitive high-grade serous ovarian cancer, PR in 16% (3/19) and stable disease over 120 days in 16% (3/19) of patients with plantinum-resistant high-grade serous ovarian cancer (PMID: 23810788; NCT00749502) | 23810788 |
| Unknown unknown | prostate cancer | not applicable | PARP Inhibitor (Pan) | Niraparib | Phase I | Actionable | In a Phase I trial, Zejula (niraparib) treatment resulted in stable diseases with a median duration of 254 days in 43% (9/21) of patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502). | 23810788 |
| Unknown unknown | ovary epithelial cancer | not applicable | PARP Inhibitor (Pan) | Niraparib | FDA approved | Actionable | In a Phase III trial (NOVA) that supported FDA approval, maintenance therapy with Zejula (niraparib) improved median progression-free survival compared to placebo in germline BRCA mutant (21.0 vs. 5.5 mo., HR=0.27) and germline BRCA wild-type (9.3 vs. 3.9 mo, HR=0.45) patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, who had a complete or partial response to 2 or more prior platinum therapies (PMID: 27717299; NCT01847274). | detail... 27717299 |
| Unknown unknown | ovary epithelial cancer | not applicable | PARP Inhibitor (Pan) | Niraparib | FDA approved | Actionable | In a Phase III trial (PRIMA) that supported FDA approval, maintenance therapy with Zejula (niraparib) significantly improved progression-free survival compared to placebo in homologous-recombination deficient (21.9 vs 10.4 months, HR=0.43, p<0.001) and the overall (13.8 vs 8.2 months, HR=0.62, p<0.001) populations of patients with newly diagnosed advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer who had a response to platinum-based chemotherapy (PMID: 31562799; NCT02655016). | 31562799 detail... |
| Unknown unknown | brain stem glioma | not applicable | PARP Inhibitor (Pan) | Niraparib + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse intrinsic pontine glioma cell line treated with a combination of ionizing radiation and Zejula (niraparib) in culture demonstrated a greater reduction in cell survival compared to either agent alone (PMID: 26351319). | 26351319 |
| Unknown unknown | malignant astrocytoma | not applicable | PARP Inhibitor (Pan) | Niraparib + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a pediatric high grade astrocytoma cell line treated with a combination of ionizing radiation and Zejula (niraparib) demonstrated a greater reduction in cell survival in culture and a better survival benefit in xenograft models compared to either agent alone (PMID: 26351319). | 26351319 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | Niraparib + SN-38 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with SN-38 combined with Zejula (niraparib) demonstrated synergism in Ewing sarcoma cells in culture, resulting in reduced cell viability (PMID: 26438158). | 26438158 |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | PARP Inhibitor (Pan) | Niraparib + SY-1365 | Preclinical - Cell culture | Actionable | In a preclinical study, SY-1365 and Zejula (niraparib) synergistically induced apoptosis in triple-receptor negative breast cancer cells in culture (Proceedings of the AACR, Vol 58, April 2017, Abstract # 1151). | detail... |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | Niraparib + Temozolomide | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Temodar (temozolomide) combined with Zejula (niraparib) demonstrated strong synergism in Ewing sarcoma cells in culture, resulting in decreased cell viability (PMID: 26438158). | 26438158 |
| Unknown unknown | prostate cancer | not applicable | PARP Inhibitor (Pan) | Abiraterone + Olaparib | Phase II | Actionable | In a Phase II trial, treatment with the combination of Lynparza (olaparib) and Zytiga (abiraterone) resulted in a prolonged median radiographic progression-free survival of 13.8 months, compared to 8.2 months with placebo plus Zytiga (abiraterone), in patients with metastatic castration-resistant prostate cancer (PMID: 29880291; NCT01972217). | 29880291 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | Adavosertib + Olaparib | Phase Ib/II | Actionable | In a Phase Ib trial, Adavosertib (MK-1775) and Lynparza (olaparib) combination therapy resulted in partial response in 17% (1/6) and stable disease in 67% (4/6) of patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 5562)). | detail... |
| Unknown unknown | ovary epithelial cancer | not applicable | PARP Inhibitor (Pan) | Alpelisib + Olaparib | Phase I | Actionable | In a Phase Ib trial, Alpelisib (BYL719) and Lynparza (olaparib) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 36% (10/28) and stable disease in 50% (14/28) of patients with epithelial ovarian cancer, overall response rate was similar for germline BRCA mutated and wild-type patients (30%, 3/10 vs 35%, 6/17, p=0.42) (PMID: 30880072; NCT01623349). | 30880072 |
| Unknown unknown | glioblastoma | not applicable | PARP Inhibitor (Pan) | AsiDNA + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA treatment led to increased sensitivity to Lynparza (olaparib), resulting in decreased survival of glioblastoma cell lines in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | colon cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA treatment led to increased sensitivity to Lynparza (olaparib), resulting in decreased survival in colon cancer cell lines in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | head and neck cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA treatment led to increased sensitivity to Lynparza (olaparib), resulting in decreased survival of a head and neck cancer cell line in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | hematologic cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA treatment sensitized hematologic cancer cell lines to Lynparza (olaparib), inhibiting survival in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | melanoma | not applicable | PARP Inhibitor (Pan) | AsiDNA + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA treatment led to increased sensitivity to Lynparza (olaparib), resulting in decreased survival of melanoma cell lines in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | cervical cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA treatment led to increased sensitivity to Lynparza (olaparib), resulting in decreased survival in a cervical cancer cell line in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA treatment resulted in increased sensitivity to Lynparza (olaparib), inhibiting DNA repair and cell proliferation, and inducing death in breast cancer cell lines in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | head and neck cancer | not applicable | PARP Inhibitor (Pan) | AZD7648 + Olaparib | Preclinical - Pdx | Actionable | In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment inhibited tumor growth in a patient-derived xenograft (PDX) model of head and neck cancer harboring mutant TP53 and wild-type ATM (PMID: 31699977). | 31699977 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | AZD7648 + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment inhibited viability of ovarian cancer cell lines harboring wild-type ATM in culture (PMID: 31699977). | 31699977 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | Capivasertib + Olaparib | Phase I | Actionable | In a Phase I trial, Capivasertib (AZD5363) and Lynparza (olaparib) combination therapy was well-tolerated, and resulted in a clinical benefit rate of 44.6% (25/56, 14 partial responses, 11 stable disease >= 4 months) in patients with advanced solid tumors (PMID: 32532747; NCT02338622). | 32532747 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Capivasertib + Olaparib | Phase I | Actionable | In a Phase I trial, the combination of AZD5363 and Lynparza (olaparib) was well-tolerated and demonstrated preliminary activity in patients with endometrial, ovarian, or triple-negative breast cancer (TNBC), with an overall response rate of 24% (7/30; all partial responses, 1 ovarian, 4 endometrial, and 2 TNBC) and stable disease for greater than 4 months in 6 additional patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #391P; NCT02208375). | detail... |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | PARP Inhibitor (Pan) | Capivasertib + Olaparib | Phase I | Actionable | In a Phase I trial, the combination of AZD5363 and Lynparza (olaparib) was well-tolerated and demonstrated preliminary activity in patients with endometrial, ovarian, or triple-negative breast cancer (TNBC), with an overall response rate of 24% (7/30; all partial responses, 1 ovarian, 4 endometrial, and 2 TNBC) and stable disease for greater than 4 months in 6 additional patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #391P; NCT02208375). | detail... |
| Unknown unknown | endometrial cancer | not applicable | PARP Inhibitor (Pan) | Capivasertib + Olaparib | Phase I | Actionable | In a Phase I trial, the combination of AZD5363 and Lynparza (olaparib) was well-tolerated and demonstrated preliminary activity in patients with endometrial, ovarian, or triple-negative breast cancer (TNBC), with an overall response rate of 24% (7/30; all partial responses, 1 ovarian, 4 endometrial, and 2 TNBC) and stable disease for greater than 4 months in 6 additional patients, and a response rate of 50% (4/8) in endometrial cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #391P; NCT02208375). | detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | CCT241533 + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, CCT241533 enhanced the growth inhibition effects of Lynparza (olaparib) in cancer cells in culture (PMID: 21239475). | 21239475 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Cediranib + Durvalumab + Olaparib | Phase I | Actionable | In a Phase I trial, the combination of Cediranib (AZD-2171), Imfinzi (durvalumab), and Lynparza (olaparib) treatment demonstrated tolerability and activity in female patients with ovarian, endometrial, or triple-negative breast cancer, with a response rate of 33% (3/9; 2 pts with ovarian cancer, and 1 pt with endometrial cancer), and stable disease in 4/9 pts (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #390P; NCT02484404). | detail... |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Cediranib + Olaparib | Phase I | Actionable | In a Phase I clinical trial, the combination therapy of Cediranib (AZD-2171) and Lynparza (olaparib) demonstrated safety and efficacy in patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr LBA5500)). | detail... |
| Unknown unknown | ovary serous adenocarcinoma | not applicable | PARP Inhibitor (Pan) | Cediranib + Olaparib | Phase II | Actionable | In a Phase II trial, Cediranib (AZD-2171) and Lynparza (olaparib) treatment was well-tolerated, and resulted in an objective response (OR) of 9% (all partial), a 16-week progression-free survival (PFS) of 47%, and a disease control rate (DCR) of 68% in serous ovarian cancer patients (n=34), with an OR of 0%, 20%, 8%, 16-week PFS of 55%, 50%, 39%, and a DCR of 82%, 60%, 62% in platinum-sensitive (n=11), platinum-resistant (n=10), and exploratory cohorts (n=13), respectively (PMID: 32444417; NCT02681237). | 32444417 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | CHIR99021 + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with CHIR99021 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Lynparza (olaparib) in culture, resulting in a synergistic effect (PMID: 33589588). | 33589588 |
| Unknown unknown | oral squamous cell carcinoma | not applicable | PARP Inhibitor (Pan) | Cisplatin + Olaparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment of oral squamous carcinoma cells with Platinol (cisplatin) and Lynparza (olaparib) resulted in a synergistic effect demonstrating increased apoptosis and tumor growth inhibition in culture and cell line xenograft models (PMID: 26927065). | 26927065 |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | CYT01B + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, CYT01B and Lynparza (olaparib) synergistically inhibited growth of tumor cell lines in culture (AACR Annual Meeting 2019, Abstract 363). | detail... |
| Unknown unknown | prostate cancer | not applicable | PARP Inhibitor (Pan) | Durvalumab + Olaparib | Phase II | Actionable | In a Phase II trial, Imfinzi (durvalumab) plus Lynparza (olaparib) resulted in a decrease in PSA greater than or equal to 50% in 53% (9/17) of patients with metastatic castrate-resistant prostate cancer, with radiographic response in 4 of those 9, a median radiographic progression-free survival (PFS) of 16.1 mo., and a 12-mo. PFS probability of 83.3% in patients with mutations in DNA damage response (DDR) genes, compared to 36.4% in patients without DDR gene mutations (PMID: 30514390; NCT02484404). | 30514390 |
| Unknown unknown | female reproductive organ cancer | not applicable | PARP Inhibitor (Pan) | Durvalumab + Olaparib | Phase I | Actionable | In a Phase I trial, the combination therapy of Imfinzi (durvalumab) and Lynparza (olaparib) resulted in an overall response rate of 17% (2/12) and disease control rate of 83% (10/12) in patients with female reproductive organ cancer (PMID: 28471727). | 28471727 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Durvalumab + Olaparib | Phase II | Actionable | In a Phase II trial, combination treatment with Imfinzi (durvalumab) and Lynparza (olaparib) did not meet the primary endpoint, but led to tumor immunomodulatory effects in patients with recurrent ovarian cancer and resulted in an overall response rate of 14% (5/35, all partial responses), a median progression-free survival of 3.9 months, and a disease control rate of 71% (25/35), including 12 patients that maintained a partial response or stable disease for more than 6 months (PMID: 32398324; NCT02484404). | 32398324 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | LY2090314 + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with LY2090314 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Lynparza (olaparib) in culture, resulting in a synergistic effect (PMID: 33589588). | 33589588 |
| Unknown unknown | head and neck cancer | not applicable | PARP Inhibitor (Pan) | Olaparib | Preclinical - Pdx | Actionable | In a preclinical study, a patient-dervived xenograft (PDX) model of head and neck cancer harboring mutant TP53 and wild-type ATM did not demonstrate sensitivity to Lynparza (olaparib) treatment (PMID: 31699977). | 31699977 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Olaparib | FDA approved | Actionable | In a Phase II trial that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved progression-free survival compared to placebo (8.4 vs 4.8 mo, HR=0.35, p<0.001) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneum cancer (PMID: 22452356; NCT00753545). | 22452356 detail... |
| Unknown unknown | colorectal cancer | no benefit | PARP Inhibitor (Pan) | Olaparib | Phase II | Actionable | In a Phase II clinical trial, treatment with Lynparza (olaparib) did not result in clinical activity in colorectal cancer patients that had progressed on prior standard therapy, including both microsatellite-stable patients and those that demonstrated high microsatellite instability (PMID: 26786262). | 26786262 |
| Unknown unknown | prostate cancer | not applicable | PARP Inhibitor (Pan) | Olaparib | Phase II | Actionable | In a Phase II clinical trial, 86.7% (13/15) of metastatic castration-resistant prostate cancer patients with mutations in DNA repair genes demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322). | detail... |
| Unknown unknown | malignant astrocytoma | not applicable | PARP Inhibitor (Pan) | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) resulted in decreased cell viability of some pediatric high grade astrocytoma cell lines in culture (PMID: 26351319). | 26351319 |
| Unknown unknown | brain stem glioma | not applicable | PARP Inhibitor (Pan) | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) resulted in decreased cell viability of some diffuse intrinsic pontine glioma cell lines in culture (PMID: 26351319). | 26351319 |
| Unknown unknown | stomach cancer | not applicable | PARP Inhibitor (Pan) | Olaparib + Paclitaxel | Phase II | Actionable | In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (3.91 vs 3.55 months) compared to Taxol alone, but did significantly prolong overall survival (13.1 vs 8.3 months) in patients with metastatic gastric cancer (PMID: 26282658; NCT01063517). | 26282658 |
| Unknown unknown | stomach cancer | not applicable | PARP Inhibitor (Pan) | Olaparib + Paclitaxel | Phase III | Actionable | In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (8.8 vs 6.9 months, HR=0.79, p=0.026) compared to Taxol (paclitaxel) alone in Asian patients with advanced gastric cancer (PMID: 29103871; NCT01924533). | 29103871 |
| Unknown unknown | glioblastoma | not applicable | PARP Inhibitor (Pan) | Olaparib + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) enhanced the sensitivity of glioblastoma cell lines to radiation therapy in culture, demonstrating greater decreased cell survival when compared to cells not treated with Lynparza (olaparib) (PMID: 32347934). | 32347934 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | Olaparib + SN-38 | Preclinical - Cell culture | Actionable | In a preclinical study, Ewing sarcoma cells treated with SN-38 combined with Lynparza (olaparib) resulted in synergism, demonstrating reduced cell viability in culture (PMID: 26438158). | 26438158 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | Olaparib + SN-38 + Temozolomide | Preclinical - Cell culture | Actionable | In a preclinical study, Ewing sarcoma cells treated with the combination of Temodar (temozolomide), SN-38, and Lynparza (olaparib) had a much greater effect on decreasing cell viability and inducing apoptosis when compared to each treatment administered as a single agent or as dual agents in culture (PMID: 26438158). | 26438158 |
| Unknown unknown | Ewing sarcoma | not applicable | PARP Inhibitor (Pan) | Olaparib + Temozolomide | Preclinical - Cell culture | Actionable | In a preclinical study, Ewing sarcoma cells treated with Temodar (temozolomide) combined with Lynparza (olaparib) resulted in very strong synergism, inducing apoptosis and reducing cell viability in culture (PMID: 26438158). | 26438158 |
| Unknown unknown | glioblastoma | not applicable | PARP Inhibitor (Pan) | Olaparib + Temozolomide | Phase II | Actionable | In a Phase II trial (OPARATIC), 36% (14/39) of evaluable patients with glioblastoma were progression-free at 6 months when treated with the combination therapy of Lynparza (olaparib) and Temodar (temozolomide) (PMID: 32347934; NCT0139057). | 32347934 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | Olaparib + Temozolomide | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the addition of Lynparza (olaparib) to Temodar (temozolomide) resulted in greater antitumor activity than Temodar (temozolomide) alone in colorectal cancer cell line xenograft models, demonstrating decreased tumor volume (PMID: 27550455). | 27550455 |
| Unknown unknown | lung small cell carcinoma | not applicable | PARP Inhibitor (Pan) | Olaparib + Temozolomide | Phase Ib/II | Actionable | In a Phase I/II trial, combination of Lynparza (olaparib) and Temodar (temozolomide) resulted in an objective response rate of 41.7% (20/48) in patients with relapsed small cell lung cancer, with a median progression-free survival of 4.2 months and a median overall survival of 8.5 months, similar response was recapitulated in a coclinical trial with 32 patient-derived xenograft models (PMID: 31416802; NCT02446704). | 31416802 |
| Unknown unknown | prostate cancer | not applicable | PARP Inhibitor (Pan) | Olaparib + THZ1 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) combined with THZ1 resulted in a synergistic effect in homologous recombination-proficient prostate cancer cells, demonstrating decreased cell survival and reduced anchorage-independent growth in culture (PMID: 32668240). | 32668240 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | Olaparib + THZ1 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) combined with THZ1 resulted in a synergistic effect in homologous recombination-proficient ovarian cancer cells, demonstrating decreased cell survival and reduced anchorage-independent growth in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 32668240). | 32668240 |
| Unknown unknown | triple-receptor negative breast cancer | not applicable | PARP Inhibitor (Pan) | Olaparib + THZ1 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Lynparza (olaparib) treatment combined with THZ1 resulted in a synergistic effect in homologous recombination-proficient triple-receptor negative breast cancer cells, demonstrating decreased cell survival and anchorage-independent growth in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 32668240). | 32668240 |
| Unknown unknown | sarcoma | not applicable | PARP Inhibitor (Pan) | Olaparib + Trabectedin | Phase Ib/II | Actionable | In a Phase Ib trial, 14% (7/50) of patients with either bone or soft tissue sarcoma demonstrated a partial response according to RECIST criteria when treated with the combination therapy of Lynparza (olaparib) and Yondelis (trabectedin) (PMID: 30217671). | 30217671 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | Carboplatin + E7449 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of E7449 and Paraplatin (carboplatin) synergized to inhibit tumor growth in a human breast cancer cell line xenograft model (PMID: 26513298). | 26513298 |
| Unknown unknown | pancreatic cancer | not applicable | PARP Inhibitor (Pan) | E7449 | Phase I | Actionable | In a Phase I trial, E7449 treatment inhibited Parp activity in peripheral blood mononuclear cells and resulted in stable disease for more than 24 weeks in 7 patients with pancreatic cancer (J Clin Oncol 36, 2018 (suppl; abstr 2505); abstr e19531; NCT01618136). | detail... |
| Unknown unknown | Advanced Solid Tumor | not applicable | PARP Inhibitor (Pan) | E7449 | Phase I | Actionable | In a Phase I trial, E7449 treatment demonstrated safety and resulted in an overall response rate of 4.9% (2/41, partial responses) and stable disease in 31.7% (13/41) of patients with advanced solid tumors, including stable disease lasting greater than 23 weeks in 8 patients (PMID: 32523090; NCT01618136). | 32523090 |
| Unknown unknown | ovarian cancer | not applicable | PARP Inhibitor (Pan) | E7449 | Phase I | Actionable | In a Phase I trial, E7449 treatment inhibited Parp activity in peripheral blood mononuclear cells and resulted in partial response in 40% (2/5) of the patients with ovarian cancer (J Clin Oncol 36, 2018 (suppl; abstr 2505); abstr e19531; NCT01618136). | detail... |
| Unknown unknown | melanoma | not applicable | PARP Inhibitor (Pan) | E7449 + Temozolomide | Preclinical | Actionable | In a preclinical study, the combination of E7449 and Temodar (temozolomide) inhibited tumor growth in mouse melanoma models, with increased efficacy compared to either agent alone (PMID: 26513298). | 26513298 |
| Unknown unknown | breast cancer | not applicable | PARP Inhibitor (Pan) | AsiDNA + AZD2461 | Preclinical - Cell culture | Actionable | In a preclinical study, AsiDNA and AZD2461 combination treatment resulted in increased cell death and inhibition of proliferation in breast cancer cell lines compared to AZD2461 alone in culture (PMID: 27559053). | 27559053 |
| Unknown unknown | colorectal cancer | not applicable | PARP Inhibitor (Pan) | AZD2461 + Temozolomide | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the addition of AZD2461 to Temodar (temozolomide) resulted in greater antitumor activity than Temodar (temozolomide) alone in colorectal cancer cell line xenograft models, demonstrating decreased tumor volume (PMID: 27550455). | 27550455 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|